View Older Stories View More Recent Stories

Aug 1, 2022 04:05PM Prothena to Report Second Quarter 2022 Financial Results on August 8th
Jul 1, 2022 04:16PM Prothena Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Jul 1, 2022 04:16PM Prothena Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Jun 2, 2022 04:05PM Prothena to Participate in Jefferies Healthcare Conference
Jun 2, 2022 04:05PM Prothena to Participate in Jefferies Healthcare Conference
May 5, 2022 04:05PM Prothena Reports First Quarter 2022 Financial Results and Business Highlights
May 5, 2022 04:05PM Prothena Reports First Quarter 2022 Financial Results and Business Highlights
Apr 28, 2022 04:05PM Prothena to Report First Quarter 2022 Financial Results on May 5th
Apr 28, 2022 04:05PM Prothena to Report First Quarter 2022 Financial Results on May 5th
Apr 26, 2022 08:30AM Prothena Corp. (PRTA) Granted FDA Fast Track Designation for PRX012
Apr 26, 2022 08:30AM Prothena Receives FDA Fast Track Designation for PRX012, a Next-Generation Anti-Amyloid Beta Antibody Under Investigation for the Treatment of Alzheimer’s Disease
Apr 26, 2022 08:30AM Prothena Receives FDA Fast Track Designation for PRX012, a Next-Generation Anti-Amyloid Beta Antibody Under Investigation for the Treatment of Alzheimer’s Disease
Mar 28, 2022 08:30AM Prothena Corp. (PRTA) Announces FDA Clearance of IND for PRX012, a Subcutaneous Anti-Amyloid Beta Antibody Under Investigation for the Treatment of Alzheimer’s Disease
Mar 28, 2022 08:30AM Prothena Announces FDA Clearance of IND for PRX012, a Subcutaneous Anti-Amyloid Beta Antibody Under Investigation for the Treatment of Alzheimer’s Disease
Mar 28, 2022 08:30AM Prothena Announces FDA Clearance of IND for PRX012, a Subcutaneous Anti-Amyloid Beta Antibody Under Investigation for the Treatment of Alzheimer’s Disease
Mar 21, 2022 04:05PM Prothena to Participate in Stifel 2022 Virtual CNS Days
Mar 21, 2022 04:05PM Prothena to Participate in Stifel 2022 Virtual CNS Days
Mar 16, 2022 05:48AM Prothena Corp. (PRTA) Presents Data for Alzheimer’s and Parkinson’s Disease Programs
Mar 16, 2022 05:30AM Prothena Presents New Data for Alzheimer’s and Parkinson’s Disease Programs at AD/PD 2022
Mar 16, 2022 05:30AM Prothena Presents New Data for Alzheimer’s and Parkinson’s Disease Programs at AD/PD 2022
Feb 17, 2022 04:05PM Prothena Reports Fourth Quarter and Full Year 2021 Financial Results, and Provides Financial Guidance and Business Highlights
Feb 17, 2022 04:05PM Prothena Reports Fourth Quarter and Full Year 2021 Financial Results, and Provides Financial Guidance and Business Highlights
Feb 10, 2022 04:05PM Prothena to Report Fourth Quarter and Full Year 2021 Financial Results and Host Webcast Conference Call on February 17, 2022
Feb 10, 2022 04:05PM Prothena to Report Fourth Quarter and Full Year 2021 Financial Results and Host Webcast Conference Call on February 17, 2022
Nov 29, 2021 04:05PM Prothena to Participate in JMP Securities Hematology and Oncology Summit
Nov 29, 2021 04:05PM Prothena to Participate in JMP Securities Hematology and Oncology Summit
Nov 4, 2021 04:05PM Prothena Reports Third Quarter 2021 Financial Results and Business Highlights
Nov 4, 2021 04:05PM Prothena Reports Third Quarter 2021 Financial Results and Business Highlights
Oct 28, 2021 04:05PM Prothena to Report Third Quarter 2021 Financial Results on November 4th
Oct 28, 2021 04:05PM Prothena to Report Third Quarter 2021 Financial Results on November 4th
Oct 1, 2021 04:30PM Prothena Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Oct 1, 2021 04:30PM Prothena Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Oct 1, 2021 04:05PM Prothena Announces Executive Appointments
Oct 1, 2021 04:05PM Prothena Announces Executive Appointments
Sep 3, 2021 04:05PM Prothena Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Sep 3, 2021 04:05PM Prothena Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Sep 1, 2021 04:05PM Prothena to Participate in Upcoming September Healthcare Conferences
Sep 1, 2021 04:05PM Prothena to Participate in Upcoming September Healthcare Conferences
Aug 5, 2021 04:05PM Prothena Reports Second Quarter 2021 Financial Results and Business Highlights
Aug 5, 2021 04:05PM Prothena Reports Second Quarter 2021 Financial Results and Business Highlights
Jul 29, 2021 04:05PM Prothena to Report Second Quarter 2021 Financial Results on August 5th
Jul 29, 2021 04:05PM Prothena to Report Second Quarter 2021 Financial Results on August 5th
Jul 26, 2021 09:02AM Prothena Corp. (PRTA) Presents New Data from Robust Alzheimer’s Portfolio at the Alzheimer’s Association International Conference 2021
Jul 26, 2021 09:00AM Prothena Presents New Data from Robust Alzheimer’s Portfolio at the Alzheimer’s Association International Conference 2021
Jul 26, 2021 09:00AM Prothena Presents New Data from Robust Alzheimer’s Portfolio at the Alzheimer’s Association International Conference 2021
Jul 20, 2021 04:05PM Prothena to Present Data from Two of its Alzheimer’s Disease Programs at the Alzheimer’s Association International Conference 2021
Jul 20, 2021 04:05PM Prothena to Present Data from Two of its Alzheimer’s Disease Programs at the Alzheimer’s Association International Conference 2021
Jul 12, 2021 07:02AM Prothena Corp. (PRTA) and Novo Nordisk (NVO) Announce Acquisition Agreement for Prothena’s ATTR Amyloidosis Programme
Jul 12, 2021 07:00AM Prothena and Novo Nordisk Announce Acquisition Agreement for Prothena’s ATTR Amyloidosis Programme
Jul 12, 2021 07:00AM Prothena and Novo Nordisk Announce Acquisition Agreement for Prothena’s ATTR Amyloidosis Programme
View More Recent Stories View Older Stories